Regeneron Hits Milestones with Lynozyfic Approval and Ophthalmology Advances in Q1 2025
Regeneron Pharmaceuticals Inc. made significant strides in the first quarter of 2025, with notable developments in oncology and ophthalmology, solidifying its position as a leader in the biotechnology industry.
- Regeneron Pharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read